Is the MHRA pause because psilocybin is actually unsafe?

Not quite. The letter does not say psilocybin itself is dangerous. What it says is that one measure in one trial raised a flag, and the regulator pressed pause while that gets examined. The distinction matters, because the question is not whether the compound works or is safe in general, it is whether this specific trial design is asking the right questions in the right way. What part of this would help you most to understand first?

What does this mean if I was hoping to access treatment soon?

Honestly, it complicates the timeline, but it does not close the door. The pause is about how we measure outcomes and what standards regulators expect, not a verdict on the therapy itself. The uncertainty is hard, I know. Where does this leave you right now in terms of what you were planning?

What the MHRA Pathways pause really tells us

Substack 21 February 2026

What the MHRA Pathways pause really tells us clinically

The MHRA has paused the Pathways trial, and the headlines have done what headlines do: simplified, alarmed, and moved on. Reading the letter carefully as a clinician tells a more complicated story, one that raises as many questions about the regulatory process as it does about the trial itself.

The pause on the Pathways trial has raised urgent questions for clinicians and patients alike. Rather than treating the MHRA letter as the final word, it is worth reading it carefully as a clinician would: examining what evidence it presents, what it acknowledges, and what it deliberately leaves unaddressed.

This analysis moves beyond the headlines to consider what a clinical reading of the letter reveals about the regulatory process, the trial design, and the gaps in our current understanding. There are legitimate questions to ask not just about why the trial was paused, but about whether we are focusing on the right outcomes and the right evidence.

Read the full piece to explore what the MHRA letter actually says, where the clinical concerns lie, and what questions we should be pressing for answers to.

In response to: The Pathways Trial Has Been Paused. But Are We Asking the Right Questions? (Substack)